BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 33065080)

  • 1. Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS).
    Kawashima H; Tomaniak M; Ono M; Wang R; Hara H; Gao C; Takahashi K; Sharif F; Thury A; Suryapranata H; Walsh S; Cotton J; Carrie D; Sabate M; Steinwender C; Leibundgut G; Wykrzykowska J; de Winter RJ; Garg S; Hamm C; Steg PG; Jüni P; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW
    Am J Cardiol; 2021 Jan; 138():1-10. PubMed ID: 33065080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
    Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
    Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial.
    Chichareon P; Modolo R; Kerkmeijer L; Tomaniak M; Kogame N; Takahashi K; Chang CC; Komiyama H; Moccetti T; Talwar S; Colombo A; Maillard L; Barlis P; Wykrzykowska J; Piek JJ; Garg S; Hamm C; Steg PG; Jüni P; Valgimigli M; Windecker S; Onuma Y; Mehran R; Serruys PW
    JAMA Cardiol; 2020 Jan; 5(1):21-29. PubMed ID: 31693078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.
    Serruys PW; Takahashi K; Chichareon P; Kogame N; Tomaniak M; Modolo R; Chang CC; Komiyama H; Soliman O; Wykrzykowska JJ; de Winter RJ; Ferrario M; Dominici M; Buszman P; Bolognese L; Tumscitz C; Benit E; Stoll HP; Hamm C; Steg PG; Onuma Y; Jüni P; Windecker S; Vranckx P; Colombo A; Valgimigli M
    Eur Heart J; 2019 Aug; 40(31):2595-2604. PubMed ID: 31397487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
    Ge Z; Kan J; Gao X; Raza A; Zhang JJ; Mohydin BS; Gao F; Shao Y; Wang Y; Zeng H; Li F; Khan HS; Mengal N; Cong H; Wang M; Chen L; Wei Y; Chen F; Stone GW; Chen SL;
    Lancet; 2024 May; 403(10439):1866-1878. PubMed ID: 38599220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design.
    Kim C; Hong SJ; Shin DH; Kim BK; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Am Heart J; 2019 Jun; 212():45-52. PubMed ID: 30933857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial.
    Tomaniak M; Chichareon P; Klimczak-Tomaniak D; Takahashi K; Kogame N; Modolo R; Wang R; Ono M; Hara H; Gao C; Kawashima H; Rademaker-Havinga T; Garg S; Curzen N; Haude M; Kochman J; Gori T; Montalescot G; Angiolillo DJ; Capodanno D; Storey RF; Hamm C; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW; Anderson R
    Clin Res Cardiol; 2020 Jul; 109(7):930-943. PubMed ID: 31925529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial.
    Ono M; Chichareon P; Tomaniak M; Kawashima H; Takahashi K; Kogame N; Modolo R; Hara H; Gao C; Wang R; Walsh S; Suryapranata H; da Silva PC; Cotton J; Koning R; Akin I; Rensing BJWM; Garg S; Wykrzykowska JJ; Piek JJ; Jüni P; Hamm C; Steg PG; Valgimigli M; Windecker S; Storey RF; Onuma Y; Vranckx P; Serruys PW
    Clin Res Cardiol; 2020 Sep; 109(9):1125-1139. PubMed ID: 32006156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
    Kim BK; Hong SJ; Cho YH; Yun KH; Kim YH; Suh Y; Cho JY; Her AY; Cho S; Jeon DW; Yoo SY; Cho DK; Hong BK; Kwon H; Ahn CM; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y;
    JAMA; 2020 Jun; 323(23):2407-2416. PubMed ID: 32543684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
    Song PS; Park YH; Oh JH; Song YB; Choi SH; Gwon HC; Cho DK; Rha SW; Bae JW; Jeong JO; Hahn JY;
    Am J Cardiol; 2021 Jul; 150():47-54. PubMed ID: 34011436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI.
    Takahashi K; Serruys PW; Chichareon P; Chang CC; Tomaniak M; Modolo R; Kogame N; Magro M; Chowdhary S; Eitel I; Zweiker R; Ong P; Ottesen MM; Tijssen JGP; Wykrzykowska JJ; de Winter RJ; Garg S; Stoll HP; Hamm C; Steg PG; Onuma Y; Valgimigli M; Vranckx P; Carrie D; Windecker S
    J Am Coll Cardiol; 2019 Oct; 74(16):2015-2027. PubMed ID: 31623758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial.
    Krucoff M; Spirito A; Baber U; Sartori S; Angiolillo DJ; Briguori C; Cohen DJ; Collier T; Dangas G; Dudek D; Escaned J; Gibson CM; Han YL; Huber K; Kastrati A; Kaul U; Kornowski R; Kunadian V; Vogel B; Mehta SR; Moliterno D; Sardella G; Shlofmitz RA; Sharma S; Steg PG; Pocock S; Mehran R
    Am Heart J; 2024 Jun; 272():11-22. PubMed ID: 38458371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial.
    Gao C; Tomaniak M; Takahashi K; Kawashima H; Wang R; Hara H; Ono M; Montalescot G; Garg S; Haude M; Slagboom T; Vranckx P; Valgimigli M; Windecker S; van Geuns RJ; Hamm C; Steg PG; Onuma Y; Angiolillo DJ; Serruys PW
    Cardiovasc Diabetol; 2020 Oct; 19(1):179. PubMed ID: 33066794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.
    Vranckx P; Valgimigli M; Windecker S; Steg PG; Hamm C; Jüni P; Garcia-Garcia HM; van Es GA; Serruys PW
    EuroIntervention; 2016 Nov; 12(10):1239-1245. PubMed ID: 26606735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting.
    Franzone A; McFadden E; Leonardi S; Piccolo R; Vranckx P; Serruys PW; Benit E; Liebetrau C; Janssens L; Ferrario M; Zurakowski A; Diletti R; Dominici M; Huber K; Slagboom T; Buszman P; Bolognese L; Tumscitz C; Bryniarski K; Aminian A; Vrolix M; Petrov I; Garg S; Naber C; Prokopczuk J; Hamm C; Steg PG; Heg D; Jüni P; Windecker S; Valgimigli M;
    J Am Coll Cardiol; 2019 Nov; 74(18):2223-2234. PubMed ID: 31672177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events.
    Hara H; van Klaveren D; Takahashi K; Kogame N; Chichareon P; Modolo R; Tomaniak M; Ono M; Kawashima H; Wang R; Gao C; Niethammer M; Fontos G; Angioi M; Ribeiro VG; Barbato E; Leandro S; Hamm C; Valgimigli M; Windecker S; Jüni P; Steg PG; Verbeeck J; Tijssen JGP; Sharif F; Onuma Y; Serruys PW;
    Circ Cardiovasc Qual Outcomes; 2020 Aug; 13(8):e006660. PubMed ID: 32762446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
    Vranckx P; Valgimigli M; Jüni P; Hamm C; Steg PG; Heg D; van Es GA; McFadden EP; Onuma Y; van Meijeren C; Chichareon P; Benit E; Möllmann H; Janssens L; Ferrario M; Moschovitis A; Zurakowski A; Dominici M; Van Geuns RJ; Huber K; Slagboom T; Serruys PW; Windecker S;
    Lancet; 2018 Sep; 392(10151):940-949. PubMed ID: 30166073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized evaluation of 5-month Ticagrelor monotherapy after 1-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with drug-coated balloons: REC-CAGEFREE II trial rationale and design.
    Gao C; Zhu B; Liu J; Jiang Z; Hu T; Wang Q; Liu Y; Yuan M; Li F; Zhang R; Xia J; Onuma Y; Wang D; Serruys P; Tao L;
    BMC Cardiovasc Disord; 2024 Jan; 24(1):62. PubMed ID: 38245724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
    Tomaniak M; Chichareon P; Onuma Y; Deliargyris EN; Takahashi K; Kogame N; Modolo R; Chang CC; Rademaker-Havinga T; Storey RF; Dangas GD; Bhatt DL; Angiolillo DJ; Hamm C; Valgimigli M; Windecker S; Steg PG; Vranckx P; Serruys PW;
    JAMA Cardiol; 2019 Nov; 4(11):1092-1101. PubMed ID: 31557763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
    D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
    Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.